A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Listed as NCT04440059, this PHASE2 trial focuses on Waldenstrom's Macroglobulinemia Recurrent and Waldenstrom's Macroglobulinemia Refractory and remains completed. Sponsored by Beijing InnoCare Pharma Tech Co., Ltd., it has been updated 8 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2023 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Sep 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing InnoCare Pharma Tech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Fuzhou, China , Hangzhou, China , Hefei, China , Hubei, China , Nanjing, China , Shanghai, China , Shenyang, China , Sichuan, China , Suzhou, China and 4 more locations